Ticarcillin (TIPC) の基礎的・臨床的研究のまとめ

DOI Web Site

書誌事項

タイトル別名
  • SUMMARY OF LABORATORY AND CLINICAL STUDIES ON TICARCILLIN (TIPC) IN JAPAN
  • Ticarcillin TIPC ノ キソテキ リンショウテキ ケンキュウ ノ

この論文をさがす

抄録

Ticarcillin, a new semi-synthetic penicillin, was investigated in 79 research facilities in Japan, and the results were published in the 25th General Meeting of Japan Society of Chemotherapy.<BR>Conclusions obtained with ticarcillin are described as below.<BR>1. Bacteriological results<BR>Ticarcillin has a broad antibacterial spectrum against various organisms including Pseudomonas and Proteus similarly to CBPC and SBPC, and its action is bactericidal. Ticarcillin exhibited stronger antibacterial activity than CBPC and SBPC in sensitivity distribution of clinically isolated Pseudomonas. Its treatment efficacy was superior to the above two drugs in the infection preventive experiments.<BR>2. Absorption, distribution metabolism and ercretion<BR>Ticarcillin gave high levels in serum rapidly after its intramuscular or intravenous injection, and 70-80% of the drug was excreted in urine within 6 hours after the administration.<BR>Comparison with SBPC by cross over method, serum level and urinary excretion of ticarcillin tended to be similar or slightly higher.<BR>3. Clinical results<BR>Clincal evaluations of ticarcillin were investigated on 733 cases in the fields of internal medicine, pediatrics, surgery, obstetrics and gynecology, and urology.<BR>This drug was administered mostly at a daily dose of 2-4 g divided into 2-3 times, and the efficacy rate obtained was 60 -80% in each field.<BR>Side effects of the drug were observed at 4. 4%, and these consisisted chiefly of eruption, pain at injected site and digestive symptom.<BR>No severe side effect was reported up to now.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ